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Summary
Objective: We investigated the synovial and plasma glucosamine concentrations in osteoarthritic patients following oral administration of
crystalline glucosamine sulphate at the therapeutic dose of 1500 mg once-a-day for 14 days.
Design: Twelve osteoarthritic patients (six males and six females) received 14 consecutive once-daily oral administrations of crystalline glu-
cosamine sulphate soluble powder (1500 mg), in an open fashion. Plasma and synovial ﬂuid were collected simultaneously from the same
patient, at baseline and, at steady state (3 h after the last dose). Glucosamine was determined in plasma and synovial ﬂuid by liquid chroma-
tographyetandem mass spectrometry.
Results: Median endogenous glucosamine concentrations in plasma and synovial ﬂuid were 52.0 ng/ml (0.29 mM) and 36.5 ng/ml (0.21 mM),
respectively (P¼ 0.001), and varied substantially among patients (41e121 ng/ml and <10e67 ng/ml, respectively). Three hours after the last
dose, glucosamine concentrations resulted increased from baseline in all patients with median increases of 20.5 and 21.5 folds in plasma and
synovial ﬂuid, respectively, the difference being not statistically signiﬁcant (P¼ 0.11). In plasma, the median post-treatment value was
1282 ng/ml (7.17 mM) and ranged from 600 to 4061 ng/ml (3.35e22.7 mM). The median post-treatment synovial glucosamine concentration
was 777 ng/ml (4.34 mM), i.e., signiﬁcantly lower than in plasma (P¼ 0.001), and ranged from 577 to 3248 ng/ml (3.22e18.1 mM). Plasma
and synovial glucosamine concentrations were highly correlated and were in the 10 mM range.
Conclusions: Glucosamine is bioavailable both systemically and at the site of action (the joint) after oral administration of crystalline glucos-
amine sulphate in ostaeoarthritis patients. Steady state glucosamine concentrations in plasma and synovial ﬂuid were correlated and in line
with those effective in selected in vitro studies.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Several clinical studies have indicated that crystalline glu-
cosamine sulphate is effective in controlling osteoarthritis
(OA) symptoms and disease progression1e3. In particular,
two randomised, placebo-controlled, double-blind trials of
3-year duration in knee OA patients, showed that this symp-
tom-modifying effect is sustained over long-term treatment
courses4,5. Moreover, both studies suggested that the
drug also has a structure-modifying effect, as assessed
by measurement of joint space narrowing using validated
techniques on standardised plain radiographs4,5e7. Another
recently completed trial (the GUIDE study8), conﬁrmed the
symptomatic results described above and indicated that,
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2007.at the dose of 1500 mg once-a-day, crystalline glucosamine
sulphate provided a symptomatic effect that was signiﬁ-
cantly superior to that observed after the administration of
placebo8. In the same study and depending on the selected
outcome measures, the effect observed after the adminis-
tration of the currently preferred symptomatic medication
in OA (acetaminophen) was not always different from that
observed after the administration of placebo8. The formula-
tion used in the above pivotal studies4,5,8 is the original
crystalline glucosamine sulphate 1500 mg once-a-day solu-
ble powder preparation which is a prescription drug in most
European and extra-European countries and differs from
glucosamine formulations available in the USA and other
countries. In fact, the US Dietary Supplements Health and
Education Act of 19949 favoured the appearance of several
poorly characterised dietary supplements containing either
inadequate active ingredient quantity10, or other glucos-
amine salts (e.g., hydrochloride), derivatives (e.g., N-acetyl-
glucosamine), or dosage forms and regimens. This might
also provide an explanation for the ﬁnding that when other
salts, formulations and/or daily regimens have been used
in clinical trials, the results have not been favourable11e15.
In particular, the recently completed National Institutes of764
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Intervention Trial (GAIT) trial in knee OA, indicated that
the symptomatic effect of glucosamine hydrochloride at
the dose of 500 mg t.i.d. did not differ signiﬁcantly from pla-
cebo15. This conﬁrmed the skepticism not only on the sev-
eral confounders and problematic study design for some
trials, but also on the possible suboptimal exposure of the
patients to the active drug that might also come from the
adopted dose and dosing interval16.
The selection of the optimal dose and dosing schedule for
glucosamine is made difﬁcult by the fact that the mecha-
nism of action by which the drug exerts its clinical effects
has not been fully elucidated. A major problem in this
respect has been the limited knowledge of glucosamine
pharmacokinetics after systemic and especially oral admin-
istration of glucosamine sulphate. We recently investigated
the oral bioavailability and dose proportionality of glucos-
amine in healthy volunteers after administration of crystal-
line glucosamine sulphate at the doses of 750, 1500,
and 3000 mg once daily17. The study demonstrated that
after repeated oral administrations of crystalline glucos-
amine sulphate the active drug glucosamine is available
to the systemic circulation. Glucosamine pharmacokinetics
resulted linear in the dose interval 750e1500 mg and the
steady state peak plasma concentrations at the 1500 mg
dose were in the 10 mM range17. Possible limitations of
that investigation were the lack of information regarding
the distribution of the drug at the site of action (i.e., the joint)
and the fact that the study was performed in healthy volun-
teers and not in patients. Even though other studies inves-
tigated the serum and synovial levels of glucosamine in
horses after oral administration of glucosamine hydrochlo-
ride at clinically relevant doses18, whereas other studies
investigated the serum concentrations of glucosamine in
OA patients receiving a single 1500 mg dose of glucosamine
as sulphate19 or hydrochloride20, it is currently unknown if
glucosamine reaches the joint and the possible biological
target within the joint, after oral administration of crystalline
glucosamine sulphate in OA patients.
The bioanalytical method for the determination of glucos-
amine in human plasma21 used in our previous investi-
gation in healthy volunteers17, has been recently validated
for the determination of the drug in human synovial ﬂuid.
Therefore, the availability of these bioanalytical methods
for the determination of glucosamine in both matrices
made possible the present investigation that was aimed at
assessing if glucosamine reaches the systemic circulation
and the joint after oral administration of crystalline glucos-
amine sulphate at the therapeutic dose of 1500 mg once-a-
day for 14 days in knee OA patients. The present paper
reports the results obtained and thus addresses most of
the unresolved issues related to the absorption and distribu-
tion of glucosamine in OA patients in a study designed to
mimic the conditions found during the therapeutic use of
this drug.
Methods
PATIENTS
Twelve Caucasian patients (six males and six females)
fulﬁlling the American College of Rheumatology criteria for
knee OA were recruited from the Istituti Ortopedici Rizzoli
of Bologna, Italy (Table I). A complete medical history
was obtained from each patient to exclude endocrine, met-
abolic, liver, kidney, and cardiac diseases and acute illness
such as infection and respiratory disorders. Thus, except forOA, the patients were considered otherwise healthy at
screening based on physical examination including con-
comitant drug use.
The patients were non- or mild smokers 10 cigarettes/
day and drank 5 cups of xanthine-containing beverages
(coffee/tea) per day. They understood and signed the In-
formed Consent Form.
STUDY DESIGN
The study protocol and related material were approved by
the Local Ethics Committee of the Istituti Ortopedici Rizzoli
in Bologna, Italy. The study was carried out in accordance
with the current revision of the Declaration of Helsinki con-
cerning medical research in humans, and with current Good
Clinical and Laboratory Practice Guidelines (USA and EU).
The study design was open-label, to investigate the
plasma and synovial concentrations of glucosamine before
and after repeated oral administration of the original crystal-
line glucosamine sulphate formulation at the once-a-day
dose of 1500 mg for fourteen consecutive days. Previous
studies have shown that the pharmacokinetics of glucos-
aminewereat steady stateafter 3 consecutivedays of admin-
istration of this formulation and dose regimen17. However, to
avoid unnecessary discomfort to the patients during the sec-
ond synovial ﬂuid collection, this was separated from the ﬁrst
collection by a 14-day interval during which treatment with
glucosamine sulphatewas continued. This provided theaddi-
tional beneﬁt of a study design that more closely mimics the
conditions found during the long-term therapeutic useof crys-
talline glucosamine sulphate in OA patients.
Crystalline glucosamine sulphate (Dona, Viartril-S, Xicil
or other trademarks by the Rottapharm Group, Monza, Italy)
is a deﬁned, pure and stable substance in which glucos-
amine, sulphate, chloride and sodium ions are present in
stoichiometric ratios of 2:1:2:2. Doses are deﬁned in relation
to the net content in glucosamine sulphate. The standard
formulation used in the present study consists of an oral
Table I
Subject demographic characteristics
Randomisation
n(
Age
(years)
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
Females
2 57 155 54 22.5
3 64 168 67 23.8
7 47 163 75 28.2
8 49 160 95 37.1
10 49 163 64 24.1
12 81 150 60 26.7
Median 53 161.5 65.5 25.4
Range 47e81 150e168 54e95 22.5e37.1
Males
1 48 180 85 26.2
4 61 172 76 26.0
5 65 178 105 33.1
6 56 174 92 30.4
9 25 178 78 24.7
11 61 168 91 32.2
Median 58.5 176 88 28.3
Range 25e65 168e180 76e105 22.5e33.1
Overall
Median 56.5 168 77 26.5
Range 25e81 150e180 54e105 22.5e37.1
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of the active ingredient to be taken once daily. As per cur-
rent guidelines22 the powder was dissolved each day in
240 ml of water. During the entire study period, the food
and ﬂuid intake of the patients was maintained as per in-
structions given at enrolment, to ensure adherence to the
inclusion/exclusion criteria. Apart from these restrictions,
the lifestyle of the patients remained unchanged in order
to mimic as much as possible the conditions encountered
in clinical practice. Blood was collected from the antecubital
vein into heparinised tubes, whereas synovial ﬂuid was col-
lected by aseptic arthrocentesis from the knee joint. For eth-
ical reasons, the investigators were instructed to collect
a minimum amount of synovial ﬂuid from the joint to allow
the bioanalytical determinations (approximately 1 ml) re-
gardless of the total volume of ﬂuid available. Blood and sy-
novial ﬂuid were always collected from each patient at the
same time during the same visit. Each patient underwent
two blood and synovial ﬂuid collections that were carried
out during the two scheduled visits. The ﬁrst collection of
blood and synovial ﬂuid was conducted at enrolment (time
0), i.e., before the start of the treatment period with the study
drug.Glucosamine concentrations determined in plasmaand
synovial ﬂuid collectedbefore the start of treatment allowed to
assess the endogenous glucosamine concentrations in
these biological ﬂuids. After the ﬁrst visit the patients started
the treatment periodwith the study drug that lasted for 14 con-
secutive days during which they received oral crystalline glu-
cosamine sulphate at the standard prescription dose of
1500 mg once-a-day. On the last day of treatment (day 14)
the patients returned at the study centre for the second
scheduled visit to undergo the second and last blood and sy-
novial ﬂuid collection that was carried out 3 h after the last
drug intake. The sampling time of 3 h after the last dose
was chosen based on the previous healthy volunteer study
that had shown that the steady state peak plasma concen-
trations (Css,max) occurred on average, 3 h after drug
administration17. Aliquots of plasma (obtained by blood
centrifugation at 2000 g at 4C) and synovial ﬂuid were
stored at 20C pending analysis.
Safety and tolerability were monitored throughout the
study by adverse events recording and by repeating all
the screening procedures at a follow-up visit carried out
within 7 days after the study end.
BIOANALYSIS
Glucosamine plasma and synovial ﬂuid concentrations
were determined using identical liquid chromatography
methods with mass spectrometry detection (LCeMS/MS).
Details of the method in plasma have been reported else-
where21. Brieﬂy, plasma and synovial ﬂuid samples
(0.49 ml) were added with 0.01 ml of a solution of the internal
standard (13C-glucosamine) at a ﬁnal concentration of
250 ng/ml and subjected to a protein precipitation step by
the addition of 0.25 ml of a 200 mg/ml solution of trichloro
acetic acid. The samples were then stirred on a vortex and
centrifuged at 2000 g for 20 min. The supernatants were
transferred into injection vials and a 3 ml sampling volume
was injected into the LCeMS/MS instrumentation. Separa-
tion was achieved using a mixture of acetonitrile and water
as the mobile phase in a gradient mode on an high perfor-
mance liquid chromatography (HPLC) system from Alliance
Waters (model 2695). This system was equipped with a Sho-
dex Asahipak NH2P-50G 2D column (150 mm 2.0 mm In-
ternal Diameter; particle size: 5 mm) ﬁtted with a Shodex
Asahipak NH2P-50G 2D (30 mm 2.0 mm InternalDiameter; particle size: 5 mm) guard column. The HPLC sys-
tem was connected to a mass spectrometer fromMicromass
(model Quattro-LC) operating in the positive ion mode.
Quantitative determination of glucosamine was performed
in the Multiple Reaction Monitoring mode to follow the transi-
tions 180/ 72 for glucosamine and 181/ 73 for 13C-glu-
cosamine. Calibration curves were generated using
calibration samples obtained from glucosamine free plasma
and synovial ﬂuid spiked with glucosamine at concentrations
ranging from 10 ng/ml (the limit of quantitation [LOQ] of the
methods), corresponding to a 0.06 mM concentration (based
on a glucosamine Molecular Weight of 179.17 g/mol as
a free base) up to 1000 ng/ml. Recovery was calculated us-
ing six replicate analyses at three concentrations (10, 100,
and 800 ng/ml) and ranged from 96.1% to 107.6% in plasma
and from 93.5% to 99.3% in synovial ﬂuid. The assay preci-
sion relative standard deviation% (RSD%) calculated as
mean experimental concentration/standard deviation 100
and accuracy (BIAS%) calculated as (mean experimental
concentration theoretical concentration)/theoretical con-
centration 100, were assessed both intra- and inter-day
using three concentration levels within the calibration range
analysed in six replicates. The assay precision ranged from
4.1% to 13.8% in plasma and from 4.6% to 9.7% in synovial
ﬂuid. Its accuracy ranged from3.0% to 7.0% in plasma and
from 1.3% to 7.3% in synovial ﬂuid. At the LOQ (10 ng/ml),
the within assay precision averaged 13.8% in plasma and
9.7% in synovial ﬂuid, whereas the within assay accuracy av-
eraged 4.0% in plasma and 7.3% in synovial ﬂuid.
The methods were validated according to current bio-
availability guidelines22 including bench top, long-term and
repeated freeze/thawing cycles stabilities, as well as 1:10
v/v dilution with blank human plasma and synovial ﬂuid to
be able to analyse plasma and synovial samples containing
glucosamine at concentrations as high as 9000 ng/ml.
STATISTICAL ANALYSIS
Because of the small number of patients, themain descrip-
tive statistics used for demographic data, as well as for base-
line and post-treatment glucosamine concentrations, were
themedian values and ranges. This also allowed to appropri-
ately account for concentrations below the LOQ at baseline.
The correlation between glucosamine concentrations in
plasma and synovial ﬂuid was investigated by the Pearson’s
test or, in case of values below the LOQ at baseline, by the
Spearman’s rank test and by linear regression analysis.
The Wilcoxon matched-pairs test was used to compare the
absolute plasma and synovial ﬂuid concentrations at base-
line and after treatment, as well as the median folds increase
in concentrations between plasma and synovial ﬂuid after
treatment. P< 0.05 was taken as statistically signiﬁcant. All
inferential statistical analyses were performed for the overall
group of patients and not by gender, since the power of such
analysiswould be too low, given the small number of subjects
in each gender group. However, gender data are presented
descriptively.
Results
The subject demographic characteristics are reported in
Table I, where they are grouped by gender. These charac-
teristics span over a broad range as in the general patient
population.
The actual collection times post-dosing did not differ by
more than 10% from the nominal collection time (3 h),
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procedure was conducted according to the study protocol
(data not shown).
Endogenous glucosamine was detected in plasma col-
lected from all 12 patients, whereas in synovial ﬂuid endog-
enous glucosamine was detected in 10 subjects as one
female and one male had endogenous levels below the
LOQ of the method (Table II). Baseline plasma and synovial
levels were characterised by a high degree of inter-subject
variability as sometimes observed for endogenous sub-
stances23. There was a good correlation between the
endogenous glucosamine concentrations in plasma and
synovial ﬂuid (Spearman’s r¼ 0.78, P< 0.01). On the other
hand, endogenous synovial ﬂuid concentrations were lower
(P¼ 0.001) than those in plasma (median value 45.5%
lower; Table II). In both plasma and synovial ﬂuid the en-
dogenous concentrations of glucosamine appeared to be
similar in males and females, with only a numerical trend
for higher values in males (Table II).
After 14 consecutive days of treatment with glucosamine
sulphate at the dose of 1500 mg/day, the drug was ab-
sorbed and was well detectable in plasma and synovial ﬂuid
collected from all the enrolled patients. Figures 1 and 2
show the individual increases of glucosamine concentra-
tions after the 14-day treatment period compared to pre-
treatment (baseline) values in plasma and synovial ﬂuid,
respectively. In both compartments, glucosamine concen-
trations resulted increased from baseline in all 12 enrolled
patients. As summarised in Table III, the relative increases
from baseline were similar in the two compartments, with
only a marginally higher median increase in the synovial
ﬂuid compared with plasma: 21.5 folds vs. 20.5 folds
(P¼ 0.11), suggesting that the drug has a similar distribu-
tion between the two compartments. Nevertheless, the
same Table III shows that, similarly to endogenous
levels at baseline, absolute post-treatment glucosamineconcentrations were higher in plasma than in the synovial
ﬂuid (P¼ 0.001), with a median synovial/plasma concentra-
tion ratio of 76.5% (i.e., the median concentration in syno-
vial ﬂuid was only 23.5% lower than that in plasma).
Figure 3 reports that there was a very high degree of corre-
lation between post-treatment concentrations in the two
compartments (Pearsons r¼ 0.96, P< 0.0001).
Post-treatment glucosamine concentrations were similar
between males and females in plasma and synovial ﬂuid,
with a numerical trend for slightly higher concentrations in
females (Table III), i.e., differently than the situation at base-
line (Table II). In particular, women tended to experience
higher increases from baseline concentrations in the syno-
vial ﬂuid compared to men.
There were no safety issues during or after treatment in
the present study.
Discussion
To our knowledge, this is the ﬁrst study describing the
plasma and synovial ﬂuid bioavailability of glucosamine in
OA patients receiving the medication by the oral route.
This study was conducted after repeated oral doses of the
prescription crystalline glucosamine sulphate formulation
shown to be effective in OA pivotal clinical trials4,5,8 and
thus was designed to mimic the conditions encountered
during the clinical use of the drug. The study conﬁrmed pre-
vious results that have indicated that glucosamine is avail-
able to the systemic circulation after oral administration17
and adds new data demonstrating that the drug is also
available at the site of action, i.e., the joint.
In addition, the study conﬁrmed that endogenous glucos-
amine already found in plasma collected from healthy vol-
unteers17, is also present in plasma and in synovial ﬂuid
collected from OA patients. Previous studies failed to detectTable II
Baseline glucosamine levels in plasma and synovial fluid before the start of the treatment period
Randomisation n( Plasma Synovial ﬂuid Synovial/plasma
concentration 100
ng/ml mM ng/ml mM
Females
2 50 0.28 <10 <0.06 >5
3 45 0.25 20 0.11 44
7 47 0.26 33 0.20 70
8 41 0.23 22 0.18 54
10 121 0.68 67 0.37 55
12 86 0.47 38 0.21 44
Median 48.5 0.27 27.5 0.19 49
Range 41e121 0.23e0.68 <10e67 <0.06e0.37 >5e70
Males
1 47 0.26 <10 <0.06 >4.7
4 112 0.63 53 0.30 47
5 99 0.55 52 0.29 53
6 47 0.26 35 0.20 74
9 56 0.31 44 0.25 79
11 54 0.30 57 0.32 106
Median 55 0.31 48 0.27 64
Range 47e112 0.26e0.63 <10e57 <0.06e0.32 >4.7e106
Overall
Median 52 0.29 36.5 0.21 54.5
Range 41e121 0.23e0.68 <10e67 <0.06e0.37 >4.7e106
In the overall population the difference between plasma and synovial ﬂuid concentrations is statistically signiﬁcant (P¼ 0.001).
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serum18,19,20,24e29 and in horse synovial ﬂuid18. This might
be due to the LOQ of the bioanalytical methods employed
in our studies (10 ng/ml in plasma and synovial ﬂuid) that
is much lower than those of these other investigations.
Another reason for the discrepancy in the results obtained
in different studies might be due to the fact that our study
determined glucosamine in plasma, whereas some of the
previous investigations in horses18 and OA patients19 deter-
mined glucosamine in serum. Unpublished results obtained
in our laboratories, have indicated that glucosamine is
unstable in blood left at room temperature to allow clotting.
The endogenous concentrations in both plasma and sy-
novial ﬂuid varied considerably between patients (high
inter-subject variability). This ﬁnding has been reported
previously in plasma of healthy volunteers17 and thus indi-
cates that OA is unlikely to be the cause for the observed
variability. On the other hand, the presence of endogenous
glucosamine in synovial ﬂuid might be of pathophysiological
relevance for different disease characteristics, given the
role of glucosamine in the biology of the joint30 and its ther-
apeutic effects1e8. Further studies are warranted to inves-
tigate the possible prognostic and predictive value of
endogenous glucosamine in plasma and synovial ﬂuid inOA.
Despite a good correlation between the two compart-
ments, endogenous glucosamine is present in synovial ﬂuid
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Fig. 1. Individual glucosamine concentration in plasma samples col-
lected at baseline and at the end of treatment.
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Fig. 2. Individual glucosamine concentration in synovial ﬂuid sam-
ples collected at baseline and at the end of treatment.of OA patients at concentrations that resulted around 50%
lower than those determined in plasma and were even not
detectable in two subjects. Conversely, the correlation
was stronger between the levels of exogenous glucosamine
determined at steady state, after repeated doses of crystal-
line glucosamine sulphate, in plasma and synovial ﬂuid, and
they were only approximately 25% lower in the latter, al-
though the difference was still statistically signiﬁcant. The
reason why glucosamine concentrations tend to be lower
in the synovial ﬂuid compared with the plasma is unknown
and this might be of pathophysiological relevance for the
endogenous levels (see above) where the differences are
higher. It is worth mentioning that contrarily to plasma, the
total synovial ﬂuid volume is not constant in OA patients
and may vary signiﬁcantly depending on the disease char-
acteristics and severity. In the present investigation the total
synovial ﬂuid volume was not determined as it was not fore-
seen in the study protocol for ethical reasons. It is therefore
conceivable that inter-subject variation in the synovial ﬂuid
volume might have inﬂuenced the glucosamine concentra-
tions determined, perhaps resulting in lower (and variable)
estimates of glucosamine concentrations. As a support of
this hypothesis is the ﬁnding that the overall increases
from baseline levels after treatment with crystalline glucos-
amine sulphate were similar in plasma and synovial ﬂuid
(20.5 and 21.5 median folds increases, respectively, Table
III) and did not differ signiﬁcantly. This indicates that the in-
crease from baseline values may represent a more robust
estimate of the bioavailability of the drug in this compart-
ment as this parameter takes also into account the varia-
tions in the synovial volumes. Further studies are needed
to assess the total amount of glucosamine in synovial ﬂuid
in addition to the glucosamine concentrations in this com-
partment by collection of all the available ﬂuid from the joint
by articular lavage. This study design has also been sug-
gested for studies aimed at assessing various OA bio-
markers in this compartment as described in the currently
ongoing NIH OA Initiative31. In addition, it is worth consider-
ing that while the previous healthy volunteer study17 indi-
cated that peak plasma concentrations were actually
achieved 3 h after dosing with 1500 mg crystalline glucos-
amine sulphate, i.e., the sampling time in the present inves-
tigation, it is not known whether also in the synovial ﬂuid the
peak concentrations are reached 3 h after dosing. If equilib-
rium between plasma and synovial ﬂuid occurs at later
times, the concentrations reported here in synovial ﬂuid
are likely to have been underestimated.
The ﬁnding that the increases in the concentrations of
glucosamine from baseline in plasma and in synovial ﬂuid
were similar after repeated administration of crystalline glu-
cosamine sulphate is clinically relevant, as it indicates that
for glucosamine, monitoring of the plasma drug concentra-
tion is a valid surrogate to study the fate of the drug at
the site of action. Therefore, future studies of the possible
correlation between the plasma (and therefore synovial)
glucosamine concentration increases and the therapeutic
effects, can be designed and may assess if the exposure
to glucosamine represents a predictive factor of response.
The results observed in the present study, if conﬁrmed in
larger trials, provide also the rationale for the conduction
of such investigations since they indicated that the concen-
trations of endogenous as well as exogenous glucosamine
are characterised by a high degree of inter-subject variabil-
ity, this being in line with the response rate of OA patients
that also appears to vary3.
Previous studies in horses using glucosamine hydro-
chloride have found that synovial ﬂuid glucosamine
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Glucosamine levels in plasma and synovial fluid at the end of the treatment period, three hours after the last drug administration. Folds in-
crease from baseline values are also shown between parentheses
Randomisation
n(
Plasma Synovial ﬂuid Synovial/plasma
concentration 100
ng/ml mM ng/ml mM
Females
2 600 (12) 3.35 577 (>57.7) 3.22 96
3 4061 (90) 22.7 3248 (162) 18.1 80
7 1401 (30) 7.83 1093 (33) 6.11 78
8 1309 (32) 7.31 999 (45) 5.58 76
10 1319 (11) 7.37 672 (10) 3.75 51
12 1025 (12) 5.73 758 (20) 4.23 74
Median 1314 (21) 7.34 878.5 (39) 4.91 77
Range 600e4061 (11e90) 3.35e22.7 577e3248 (10e162) 3.22e18.1 51e96
Males
1 1896 (40) 10.5 1978 (>197.8) 11.1 104
4 914 (8) 5.11 633 (12) 3.54 69
5 993 (10) 5.55 796 (15) 4.45 80
6 1297 (28) 7.25 808 (23) 4.51 62
9 1267 (23) 7.08 638 (15) 3.56 50
11 968 (18) 5.41 746 (13) 4.17 77
Median 1130 (20.5) 6.32 771 (15) 4.31 73
Range 914e1896 (8e40) 5.11e10.5 633e1978 (12e>197.8) 3.54e11.1 50e104
Overall
Median 1282 (20.5) 7.17 777 (21.5) 4.34 76.5
Range 600e4061 (8e90) 3.35e22.7 577e3248 (10e>197.8) 3.22e18.1 50e104
In the overall population, the difference between plasma and synovial ﬂuid concentrations is statistically signiﬁcant (P¼ 0.001). Conversely,
the fold increase in plasma and synovial ﬂuid concentrations did not differ signiﬁcantly (P¼ 011).concentrations were 90% lower than those observed in
serum and negligible in absolute values18. In our present
study with glucosamine sulphate the median drug concen-
tration in synovial ﬂuid were only about 25% lower than
those in plasma and not negligible in absolute values, as
they were between 4 and 5 mM, or even higher if the
mean values are considered. Therefore, the glucosamine
plasma and synovial ﬂuid concentrations were important
and in the same order of magnitude (i.e., in the 10 mM
range). Besides the use of a different glucosamine salt,
this apparent discrepancy could be due to a specie-speciﬁc
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Fig. 3. Correlation between plasma and synovial ﬂuid glucosamine
concentrations at the end of treatment. The correlation was linear
and described by the equation y¼ 0.84x 115.6 (r¼ 0.96).difference and, as stated above, to the different bioanalyti-
cal method and biological matrix used17,18.
Previous pharmacological studies have shown that glu-
cosamine is preferentially incorporated by chondrocytes
into the components of the glycosaminoglycan chains in
the intact cartilage32, stimulates the synthesis of physiolog-
ical proteoglycans33e35 and decreases the activity of cata-
bolic enzymes, including matrix metalloproteinases
(MMPs)33,35,36. Selected in vitro models33 showed that glu-
cosamine was metabolically effective at concentrations
hundred-folds lower than the average concentrations deter-
mined in plasma and synovial ﬂuid in the present study
while, on the contrary, other studies suggested that glucos-
amine was not able to stimulate glycosaminoglycan synthe-
sis at concentrations below 1 mM37. On the other hand, it is
unlikely that the clinical effects of glucosamine sulphate,
with particular regard to the symptom-modifying effects
achieved over relatively short treatment courses3,8, but
also to the putative disease-modifying activity4,5, are linked
to a mere stimulation of glycosaminoglycan synthesis. In
fact, this outdated hypothesis has been recently replaced
by the theory that the compound inhibits interleukin-1 (IL-1)-
induced gene expression, possibly via the suppression of
the cytokine intracellular signalling pathway and nuclear
factor-kappaB activation38,39 thus reversing the pro-inﬂam-
matory and joint degenerating effects of IL-136,40.While
these initial evidences were obtained at high in vitro glucos-
amine concentrations, more recent studies have shown
these effects at concentrations only slightly above those
described in the present study41, or exactly in the same
10 mM range42. Actually, crystalline glucosamine sulphate
inhibited IL-1-stimulated gene expression of cyclooxy-
genase 2 (Cox-2), inducible nitric oxide synthase (iNOS),
tumour necrosis factor-a, IL-6, IL-1, MMP-3 and
770 S. Persiani et al.: Oral glucosamine in plasma and synovial ﬂuid of OA patientsaggrecanase 2, with glucosamine IC50 ranging between 3
and 14 mM42, close or even slightly lower than those found
in both plasma and synovial ﬂuid in the present study.
Thus, the present investigation provides compelling evi-
dence that after oral administration of crystalline glucos-
amine sulphate, the active drug glucosamine reaches
pharmacologically relevant concentrations in the systemic
circulation and at the site of action.
The present study has been conducted using the once-a-
day soluble powder formulation of crystalline glucosamine
sulphate used in pivotal clinical trials4,5,8 which is a prescrip-
tion drug in most European countries. Transfer of the efﬁ-
cacy and safety data obtained with this substance and
formulation to common dietary supplements, has already
been discouraged4,5. In fact, these uncontrolled formula-
tions often have a much lower glucosamine content than
reported in their label claims and are thus commonly
underdosed10. In addition, there is currently no clinical justi-
ﬁcation to use different glucosamine compounds or even
other glucosamine salts, e.g., hydrochloride, as pivotal trials
failed to show the same beneﬁt3,11,15. In addition, a single-
dose pharmacokinetic study with the glucosamine hydro-
chloride solid preparation, at the same 1500 mg unit dose,
used in the GAIT, found glucosamine peak concentrations
in plasma that were only 3 mM20, i.e., almost three-fold lower
than the steady state concentrations reached with 1500 mg
of crystalline glucosamine sulphate and they might be even
lower in the synovial ﬂuid and, especially, when the 1500 mg
daily dose is fractioned as 500 mg three times a day as done
in GAIT and in other studies. These lower concentrations
found with glucosamine hydrochloride are less effective in
vitro on the putative mechanism of action of glucosamine de-
scribed above42 and may explain the unsatisfactory clinical
trial results of glucosamine hydrochloride11,15 compared
with the prescription glucosamine sulphate43. There are sev-
eral reasons why glucosamine hydrochloride formulations
might have a lower bioavailability than the standard prescrip-
tion glucosamine sulphate formulation. First of all, the latter
is formulated as a soluble powder for oral administration,
thus providing an extemporary liquid formulation that has
by deﬁnition, optimal and higher bioavailability compared
with a solid formulation. In addition, the different nature of
the formulation involves the use of different excipients that
may also affect bioavailability, similarly to the presence
and stoichiometric ratio of different ions in the different glu-
cosamine salts and stabilisation processes17.
Unfortunately, there are no pharmacokinetics and bio-
availability studies of other glucosamine sulphate prepara-
tions and it is therefore impossible to comment on their
clinical value relative to the prescription formulation.
Finally, the sulphate supplementation provided by glucos-
amine sulphate may signiﬁcantly contribute to its effects44,45
and it would be interesting to asses if the sulphate concen-
trations in synovial ﬂuid increase after the administration of
glucosamine sulphate. It is intriguing that the only clinically
relevant results in GAIT were seen in the subgroup of
more severe patients when glucosamine hydrochloride
was combined with chondroitin sulphate, providing further
support to the hypothesis that increasing the sulphate
concentrations may have therapeutic effects45.
Another hypothesis generated by the present study is
that of the higher plasma and synovial ﬂuid glucosamine
concentrations in females compared to males after treat-
ment with glucosamine sulphate. The difference could not
be analysed statistically (due to the small sample size),
and might be only apparent as it was not presents at base-
line (Table II). This issue should be assessed in larger,suitably designed trials taking into consideration that in
the present study, this hypothetical difference does not ap-
pear to be due to gender related differences in body mass
index (BMI) that, as shown in Table I, was similar in males
and females (27.9 and 27.1, respectively).
A possible limitation of the present study is that the bioa-
nalytical determinations although relevant from a pharmaco-
logical point of view, did not allow the determination of
glucosamine concentrations in the cartilage tissue. It has
been demonstrated that 2 h after administration of radiola-
belled glucosamine to rats and dogs, the radioactivity accu-
mulated in the knee cartilage of the treated animals with
values being 13-folds higher than those determined in
plasma46. If this is the case also for humans, the glucos-
amine concentrations achieved in the cartilage of OA pa-
tients after oral administration of crystalline glucosamine
sulphate might be much higher than those determined in
plasma and synovial ﬂuid in the present investigation.
A number of other potential limitations should be ac-
knowledged. First of all, the study is of limited size, due to
the difﬁculties and ethical restrictions in providing not only
blood, but also synovial ﬂuid samples on repeated occa-
sions. Larger patient cohorts might be recruited in future
studies to further assess the clinical effects of glucosamine
sulphate, as long as the collection of plasma and synovial
ﬂuid does not affect the efﬁcacy and safety evaluation,
which may be problematic. Larger patient samples might
also offer the opportunity to test possible differences for
gender, age groups and concomitant diseases, including
gastrointestinal function disorders. Finally, a direct compar-
ison of the bioavailability of glucosamine sulphate and glu-
cosamine hydrochloride might also be useful.
In conclusion, we have described the plasma and syno-
vial bioavailability of glucosamine after oral administration
of crystalline glucosamine sulphate in man. Our ﬁndings in-
dicate that the drug is available systemically and at the site
of action (the joint) at concentrations that are in line with
those found to be effective in in vitro models on the putative
mechanism of action of the drug, thus supporting the fa-
vourable clinical results in OA. Future studies should asses
the total amount of glucosamine in the joint and the
existence of a possible correlation to treatment response.
Additional studies should compare the bioavailability of
glucosamine at the site of action after the administration
of the prescription glucosamine sulphate formulation used
here with that of other glucosamine salts, derivatives, for-
mulations, or dose regimens. This might provide some
clues to explain the observed discrepancies in therapeutic
effects.
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